Clinical Trials of Oncolytic Viruses in Breast Cancer

by Mary E. Carter, André Koch, Ulrich M. Lauer, Andreas D. Hartkopf
Published 2021-12-01

Improved Killing of Human High-Grade Glioma Cells by Combining Ionizing Radiation with Oncolytic Parvovirus H-1 Infection

by Karsten Geletneky, Andreas D. Hartkopf, Robert Krempien, Jean Rommelaere, Joerg R. Schlehofer
Published 2010-01-01

Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis

by Cansu E. Önder, Moustafa Moustafa-Oglou, Sarah M. Schröder, Andreas D. Hartkopf, André Koch, Christian M. Seitz
Published 2023-12-01

Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer

by Cansu E. Önder, Teresa J. Ziegler, Ronja Becker, Sara Y. Brucker, Andreas D. Hartkopf, Tobias Engler, André Koch
Published 2023-07-01

Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?

by Yanjun Zhou, Jonas S. Heitmann, Korbinian N. Kropp, Martina Hinterleitner, André Koch, Andreas D. Hartkopf, Helmut R. Salih, Clemens Hinterleitner, Stefanie Maurer
Published 2021-06-01

Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer Patients

by Léa L. Volmer, Cansu E. Önder, Barbara Volz, Anjali R. Singh, Sara Y. Brucker, Tobias Engler, Andreas D. Hartkopf, André Koch
Published 2023-09-01

Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination—A Retrospective Observation

by Henning Zelba, Alex McQueeney, Armin Rabsteyn, Oliver Bartsch, Christina Kyzirakos, Simone Kayser, Johannes Harter, Pauline Latzer, Dirk Hadaschik, Florian Battke, Andreas D. Hartkopf, Saskia Biskup
Published 2022-11-01

A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy

by Mary E. Carter, Andreas D. Hartkopf, Anna Wagner, Léa L. Volmer, Sara Y. Brucker, Susanne Berchtold, Susanne Berchtold, Ulrich M. Lauer, Ulrich M. Lauer, André Koch
Published 2022-02-01

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression

by Susanne M. Rittig, Susanne M. Rittig, Martina S. Lutz, Martina S. Lutz, Kim L. Clar, Kim L. Clar, Yanjun Zhou, Yanjun Zhou, Korbinian N. Kropp, André Koch, Andreas D. Hartkopf, Andreas D. Hartkopf, Martina Hinterleitner, Martina Hinterleitner, Lars Zender, Lars Zender, Lars Zender, Helmut R. Salih, Helmut R. Salih, Stefanie Maurer, Stefanie Maurer, Stefanie Maurer, Clemens Hinterleitner, Clemens Hinterleitner, Clemens Hinterleitner
Published 2022-07-01

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer

by Polina Kaidun, Samuel J. Holzmayer, Sarah M. Greiner, Anna Seller, Christian M. Tegeler, Ilona Hagelstein, Jonas Mauermann, Tobias Engler, André Koch, Andreas D. Hartkopf, Helmut R. Salih, Melanie Märklin
Published 2023-08-01

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center

by Dominik Dannehl, Lea L. Volmer, Martin Weiss, Sabine Matovina, Eva-Maria Grischke, Ernst Oberlechner, Anna Seller, Christina B. Walter, Markus Hahn, Tobias Engler, Sara Y. Brucker, Andreas D. Hartkopf
Published 2022-03-01

Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer

by Thomas M. Deutsch, Stefan Stefanovic, Manuel Feisst, Chiara Fischer, Fabian Riedel, Carlo Fremd, Christoph Domschke, Klaus Pantel, Andreas D. Hartkopf, Marc Sutterlin, Sara Y. Brucker, Andreas Schneeweiss, Markus Wallwiener
Published 2020-04-01

Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment

by Chiara Fischer, Andrey Turchinovich, Manuel Feisst, Fabian Riedel, Kathrin Haßdenteufel, Philipp Scharli, Andreas D. Hartkopf, Sara Y. Brucker, Laura Michel, Barbara Burwinkel, Andreas Schneeweiss, Markus Wallwiener, Thomas M. Deutsch
Published 2022-08-01

Recurrence Score^® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the...

by Dominik Dannehl, Tobias Engler, Lea L. Volmer, Annette Staebler, Anna K. Fischer, Martin Weiss, Markus Hahn, Christina B. Walter, Eva-Maria Grischke, Falko Fend, Florin-Andrei Taran, Sara Y. Brucker, Andreas D. Hartkopf
Published 2022-10-01

Image‐guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake

by Qianlu Yang, Sisi Deng, Heike Preibsch, Tim‐Colin Schade, André Koch, Georgy Berezhnoy, Laimdota Zizmare, Anna Fischer, Brigitte Gückel, Annette Staebler, Andreas D. Hartkopf, Bernd J. Pichler, Christian laFougère, Markus Hahn, Irina Bonzheim, Konstantin Nikolaou, Christoph Trautwein
Published 2024-02-01

Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome

by Anna Seller, Christian M. Tegeler, Jonas Mauermann, Tatjana Schreiber, Ilona Hagelstein, Kai Liebel, André Koch, Jonas S. Heitmann, Sarah M. Greiner, Clara Hayn, Dominik Dannehl, Tobias Engler, Andreas D. Hartkopf, Markus Hahn, Sara Y. Brucker, Helmut R. Salih, Melanie Märklin
Published 2024-04-01

Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression

by Clemens Hinterleitner, Clemens Hinterleitner, Yanjun Zhou, Yanjun Zhou, Claudia Tandler, Claudia Tandler, Jonas S. Heitmann, Jonas S. Heitmann, Korbinian N. Kropp, Martina Hinterleitner, Martina Hinterleitner, André Koch, Andreas D. Hartkopf, Lars Zender, Lars Zender, Lars Zender, Helmut R. Salih, Helmut R. Salih, Stefanie Maurer, Stefanie Maurer, Stefanie Maurer
Published 2021-03-01

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

by Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Published 2020-11-01

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuz...

by Laura L. Michel, Andreas D. Hartkopf, Peter A. Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Bernhard Volz, Hanna Huebner, Pauline Wimberger, Carsten Hielscher, Christoph Mundhenke, Christian Kurbacher, Rachel Wuerstlein, Michael Untch, Friedrich Overkamp, Jens Huober, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Tanja N. Fehm
Published 2020-10-01

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

by Michael P. Lux, Naiba Nabieva, Andreas D. Hartkopf, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Diethelm Wallwiener, Andreas Schneeweiss, Sara Y. Brucker
Published 2018-12-01